Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
85
resultados
Última actualización
14/09/2026 [08:11:00]
Resultados 75 a 85 de 85
Resumen de: US20260148848A1
0000 The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma/Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).
Resumen de: EP4748932A1
The present invention refers to Annexin A8 (AnxA8) inhibitors, or pharmaceutical composition comprising thereof, for use in a method for the treatment and/or prevention of atherosclerosis. Preferably, the method comprises preventing atherosclerotic plaque formation.
Resumen de: CN122081482A
The invention provides a poor collateral circulation biomarker UBE2L3 and application thereof, and belongs to the technical field of biomedicine. According to the application disclosed by the invention, the key effect of the UBE2L3 in inhibiting the formation of the chronic coronary artery complete occlusion collateral circulation is defined for the first time, and the 'UBE2L3-Parkin-Drpl' axis is determined as a key endogenous inhibition pathway for regulating and controlling the CTO collateral circulation. The invention provides a clear intervention target with a clear mechanism for developing a brand new precise therapy for promoting therapeutic angiogenesis, solves the problems of unstable curative effect and off-target risk caused by a wide target in a current angiogenesis promoting strategy, provides a brand new non-surgical biological treatment strategy aiming at enhancing endogenous angiogenesis ability, and has a wide application prospect. Myocardial ischemia is expected to be improved essentially, so that the risk of adverse events such as long-term myocardial infarction and heart failure is reduced.
Resumen de: CN122075518A
The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and/or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and/or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal/medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.
Resumen de: CN122081474A
The invention belongs to the technical field of biological medicines, and discloses a new mutation c.311Ggt of a TNNT2 gene related to dilated cardiomyopathy. A. Family genetic analysis and in-vitro function verification prove that the mutation causes enhanced sensitivity of myocardial cells to doxorubicin and fragmentation of a mitochondrial network, and the mutation has pathogenicity. On the basis, the invention provides a specific detection primer pair and a kit, which are used for rapid gene diagnosis and risk assessment of dilated cardiomyopathy.
Resumen de: CN122071740A
The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of carbonic anhydrase IV in prevention and treatment of coronary microangiopathy. The research proves that the carbonic anhydrase IV has the effects of maintaining the activity of human microvascular endothelial cells, promoting the development of heart microvessels and protecting the barrier function of the microvessels. It is shown that the carbonic anhydrase IV can play a role in inhibiting CMVD lesion by preventing heart microvascular density reduction and inhibiting heart microvascular permeability increase in the CMVD process, and therefore the carbonic anhydrase IV has good potential practical application value.
Resumen de: US20260139229A1
0000 Provided herein are multilineage cardiovascular organoids and methods of generating the same. In some aspects, provided herein is a system comprising a plurality of multilineage cardiovascular organoids derived from embryoid bodies. The embryoid bodies can be aggregated from pluripotent stem cells of varying genotypes. The multilineage cardiovascular organoids and systems described herein may be used for screening of agents, such as anti-cancer agents, for cardiotoxicity.
Resumen de: CN122060852A
The invention discloses a biomarker and a kit for diagnosing post-stroke depression qi deficiency and blood stasis, liver depression and qi stagnation. The biomarker comprises Clcn3 and/or Nco7. According to the application, by constructing animal models with various diseases and combining ELISA and qPCR technologies, multi-dimensional verification is carried out on candidate targets, and expression changes of the candidate targets in the models are confirmed. Further, by drawing an ROC curve, the diagnostic efficiency (including AUC value, sensitivity and specificity) of each candidate marker is evaluated. Besides, an AAV-mediated RNA interference function experiment is comprehensively applied, a biomarker with diagnosis potential is deeply excavated, and a molecular basis is provided for objective diagnosis of syndromes.
Resumen de: CN122060855A
The invention discloses an application of circWHSC1 as a biomarker in preparation of a product for diagnosing or treating ineffective recanalization after ischemic stroke. According to the present invention, the circRNA sequencing results show that the expression of the circWHSC1 (including hsacirc0001388 and nucirc0001336) in the ineffective recanalization patient body is significantly reduced, and the circWHSC1 is verified in the mouse brain tissue, the plasma and the thrombus model of the tMCAO model; functional studies show that the circWHSC1 can significantly reduce the cerebral infarction volume of the mouse. The circWHSC1 can be used for early diagnosis, risk assessment, severity judgment, curative effect monitoring and prognosis judgment of invalid recanalization, and can be used as a drug target for screening candidate drugs for preventing or treating invalid recanalization. The invention provides a molecular diagnosis marker and a therapeutic target for invalid recanalization, and has important clinical value.
Nº publicación: CN122060858A 19/05/2026
Solicitante:
JILIN UNIV
\u5409\u6797\u5927\u5B66
Resumen de: CN122060858A
The invention provides a kit for diagnosing acute myocardial infarction, and belongs to the field of functions and application of genes. The kit comprises a primer pair used for detecting the expression quantity of the NEO-1 gene, a forward primer is SEQ ID NO.1, and a reverse primer is SEQ ID NO.2. By means of the primer pair, the expression quantity of the NEO-1 gene in peripheral blood can be detected, and compared with non-coronary heart disease patients, the expression of NEO-1 in peripheral blood of AMI patients is increased. The expression increase of NEO-1 is found to be an independent risk factor of AMI, and the expression quantity of NEO-1 in peripheral blood of an AMI patient can be used as one of biomarkers of AMI.
BOPI
Sede Electrónica
